Marinomed Biotech AG: Positive Outlook Amidst Strategic Turnaround

On June 30, 2025, First Berlin Equity Research initiated coverage on Marinomed Biotech AG, assigning a 'Buy' rating with a €50 target price. Marinomed, an Austrian biotech firm, enhances drug efficacy by improving the solubility of active ingredients through its patented Marinosolv® platform. This innovation is particularly beneficial for inflammatory and respiratory conditions.

The company has undergone significant financial and operational restructuring and currently adopts a dual business model. Firstly, it develops proprietary versions of established molecules, as seen with Budesolv for allergic rhinitis, aiming for out-licensing deals. Secondly, it offers Solv4U, a service for external partners focused on API solubilization.

Despite not being revolutionary, Marinomed's innovations reflect substantial progress. Budesolv has already secured a licensing agreement in Switzerland, with regulatory approval anticipated by mid-2027. Marinomed's strategic turnaround signals a potential growth phase, supported by upcoming licensing agreements and regulatory filings.